Enabling Insight-Based
Decision Making
radiomics.bio is an AI-powered medical imaging and advanced statistics clinical research organization, optimizing the development of new oncology treatments.
Who We are
radiomics.bio is a medical imaging research organization


Pioneer in the field of radiomics
radiomics.bio is an AI-powered medical imaging and advanced statistics clinical research organization, optimizing the development of new oncology treatments. radiomics.bio supports biotech and pharma companies in all stages of clinical development. At radiomics.bio we quantify treatment response, explore and validate of drug mechanisms of action, and develop predictive tools for insight-based decision making.
Advanced Image Management
Our Ikonics® platform, is a fully integrated image management platform that streamlines image collection and centralizes image quality assessment for enhanced efficiency
We ensure enhanced efficiency through our fully integrated platform, Ikonics®. Our in-house platform allows us to streamline our workflow and allows for a robust analysis process.

radiomics.bio enables insight-based decision making to optimize clinical trials and drug development studies
From image acquisition to regulatory reporting in all stages of clinical research.
Characterize disease using volumetric and radiomic imaging features to enhance understanding of disease on a patient, organ, or lesion level leading to insightful and cost-effective clinical trial designs.

Evaluate therapeutic efficiency to quantify treatment response (per arm, per dose, per indication, etc.) to facilitate objective decisions based on drug success potential for each phase of clinical development.

Characterize biological response to explore and validate the mechanisms of actions of your drug.

Predict clinical outcome using imaging and clinical data to obtain early insights during clinical trials for decision-making.


Optimize your medical image management; radiomics.bio supports the development of imaging protocols, collects and stores your images in compliance with regulatory and privacy requirements for future use, and conducts standard analysis of oncological images such as RECIST suite assessment to analyze treatment efficacy.

What’s new at radiomics.bio?

radiomics.bio Announces New Chairman

Paul Mauhin appointed Chief Financial Officer of radiomics.bio, succeeding Mathieu Delvaux

From Images to Impact: Radiomics’ Solutions to Challenges in Immunotherapy
